SCHEMBL2864064

SCHEMBL2864064

CC(C)N(C(=O)Oc1ccc(-c2cc(O)no2)cc1)c1ccc2nc(S)sc2c1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA2 P00918 4/20 0.36
THRB P10828 2/20 0.36
MAPT P10636 3/20 0.34
LMNA P02545 1/20 0.34
HPGD P15428 3/20 0.34
NPC1 O15118 3/20 0.34
RAB9A P51151 3/20 0.34
SMN1; SMN2 Q16637 3/20 0.34
TP53 P04637 3/20 0.34
PPARA Q07869 2/20 0.33
ALOX5 P09917 1/20 0.33
ALDH1A1 P00352 1/20 0.32
RECQL P46063 1/20 0.32
SMPD1 P17405 1/20 0.32
APP P05067 1/20 0.32
GLA P06280 1/20 0.32
GAA P10253 1/20 0.32
MAPK1 P28482 1/20 0.32
STAT1 P42224 1/20 0.32
HSD17B10 Q99714 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2862154 0.87 EPHX2 (0.34) CA2THRBMAPTLMNAHPGD
SCHEMBL3407752 0.85 THRB (0.36) CA2THRBMAPTLMNAHPGD
SCHEMBL2867241 0.84 MAPT (0.43) MAPTLMNAHPGDNPC1RAB9A
SCHEMBL2855117 0.83 CA2 (0.40) CA2MAPTLMNANPC1RAB9A
SCHEMBL2869556 0.81 MAPT (0.40) CA2MAPTNPC1RAB9ASMN1; SMN2
SCHEMBL2862832 0.80 CA2 (0.47) CA2TP53
SCHEMBL2866011 0.80 DYRK1A (0.39) CA2MAPTAPP
SCHEMBL2855233 0.80 MAPT (0.45) CA2MAPTPPARA
SCHEMBL2867655 0.80 WNT3A (0.36) CA2MAPTLMNANPC1RAB9A
SCHEMBL2866937 0.80 TMPRSS15 (0.36) CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1370260-B1 AZOLES AS MALONYL-COA DECARBOXYLASE INHIBITORS USEFUL AS METABOLIC MODULATORS CHUGAI PHARMACEUTICAL CO LTD (JP) 2010-11-24 EP claimed
US-7709510-B2 Azoles as malonyl-CoA decarboxylase inhibitors useful as metabolic modulators CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2010-05-04 US claimed
US-20040092503-A1 Azoles as malonyl-coa decarboxylase inhibitors useful as metabolic modulators CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2004-05-13 US claimed
EP-1370260-A2 AZOLES AS MALONYL-COA DECARBOXYLASE INHIBITORS USEFUL AS METABOLIC MODULATORS CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2003-12-17 EP claimed
WO-2002066035-A2 AZOLES AS MALONYL-COA DECARBOXYLASE INHIBITORS USEFUL AS METABOLIC MODULATORS CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2002-08-29 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040092503-A1 Azoles as malonyl-coa decarboxylase inhibitors useful as metabolic modulators ME1, ME3, ME2 CA2 297/4885THRB 3015/4885MAPT 3030/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.